Antibody-based immunotherapy in high-risk neuroblastoma

@article{Johnson2007AntibodybasedII,
  title={Antibody-based immunotherapy in high-risk neuroblastoma},
  author={Erik E. Johnson and Shannon M. Dean and P. Sondel},
  journal={Expert Reviews in Molecular Medicine},
  year={2007},
  volume={9},
  pages={1 - 21}
}
Abstract Although great advances have been made in the treatment of low- and intermediate-risk neuroblastoma in recent years, the prognosis for advanced disease remains poor. Therapies based on monoclonal antibodies that specifically target tumour cells have shown promise for treatment of high-risk neuroblastoma. This article reviews the use of monoclonal antibodies either as monotherapy or as part of a multifaceted treatment approach for advanced neuroblastoma, and explains how toxins… Expand
Anti-GD2 Strategy in the Treatment of Neuroblastoma.
Monoclonal Antibody Therapies for High Risk Neuroblastoma
  • W. Furman
  • Medicine
  • Biologics : targets & therapy
  • 2021
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
Immunotherapy for pediatric central nervous system tumors.
  • S. Gardner, N. Ahmed, H. Okada
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2010
Neuroblastoma therapy: what is in the pipeline?
...
1
2
3
4
...

References

SHOWING 1-10 OF 178 REFERENCES
Monoclonal antibody-based therapy of neuroblastoma.
Antibody-based targeted radiation to pediatric tumors.
  • S. Modak, N. Cheung
  • Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2005
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
  • N. Cheung, H. Lazarus, +7 authors N. Berger
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1987
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
  • T. Simon, B. Hero, +4 authors F. Berthold
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro
  • J. Hank, J. Surfus, +10 authors P. Sondel
  • Chemistry, Medicine
  • Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy
  • 1994
...
1
2
3
4
5
...